China
Africa
Explore chapters and articles related to this topic
Drug management
Published in Gregory YH Lip, Atrial Fibrillation in Practice, 2020
Dofetilide is a new Class III agent with promising results. In the recent placebo-controlled DIAMOND-CHF study, in patients with symptomatic congestive heart failure and left ventricular dysfunction (a high risk group) where 391 patients had AF, spontaneous cardioversion had occurred in 44% of the dofetilide group compared to 17% of the placebo group after 12 months. Dofetilide was also more effective than placebo in maintaining sinus rhythm. Other Class III agents, such as azimilide, are the subject of ongoing studies and some initial results are encouraging.
Supraventricular tachyarrhythmias in the elderly
Published in Wilbert S. Aronow, Jerome L. Fleg, Michael W. Rich, Tresch and Aronow’s Cardiovascular Disease in the Elderly, 2019
Jason T. Jacobson, Sei Iwai, Ali Ahmed, Wilbert S. Aronow
In a study of 384 patients with a history of AF or atrial flutter, azimilide lengthened the median time to first symptomatic arrhythmia recurrence from 17 days in the placebo group to 60 days in the azimilide group (167). However, additional data on both efficacy and safety of azimilide are necessary before knowing its role in clinical practice.
Prognostic impact of recurrences in patients with electrical storm
Published in Scandinavian Cardiovascular Journal, 2019
Julian Müller, Michael Behnes, Dominik Ellguth, Tobias Schupp, Kambis Mashayekhi, Martin Borggrefe, Ibrahim Akin
Clinical presentation of patients with ES may differ from asymptomatic delivery of anti-tachycardia pacing to hemodynamic instability with multiple ICD-related shocks. Presence of ES was recently shown to be associated with an increased risk of hospitalization and death compared to patients with a history of ventricular tachyarrhythmia [5]. Antiarrhythmic drugs, such as amiodarone, azimilide or dofetilide, overdrive ventricular pacing, hemodynamic support and sympathetic blockade by either beta-blocker or interventional sympathetic denervation represent established first-line therapies in ES patients. Furthermore, percutaneous catheter ablation has been recommended as another causative treatment option in selected patients [6].
Design, synthesis, and biological evaluation of arylmethylpiperidines as Kv1.5 potassium channel inhibitors
Published in Journal of Enzyme Inhibition and Medicinal Chemistry, 2022
Lingyue Zhao, Qian Yang, Yiqun Tang, Qidong You, Xiaoke Guo
In this study, we designed and synthesised a series of arylmethylpiperidines derivatives modified by DDO-02001, most of which showed effectively Kv1.5 inhibitory activities. Especially, DDO-02005 showed excellent inhibition effect of Kv1.5 with IC50 of 0.72 μM. It displayed good anti-AF effect in CaCl2-ACh AF model and effective anti-arrhythmic activity caused by aconitine. The preliminary safety of compound DDO-02005 was better than Azimilide showed by 12-lead electrocardiogram.